Literature DB >> 34099674

Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites.

Paris R Watson1, Timothy W Craven2, Xinting Li2, Stephen Rettie2,3, Parisa Hosseinzadeh2,4, Fátima Pardo-Avila5, Asim K Bera2, Vikram Khipple Mulligan2,6, Peilong Lu2,7, Alexander S Ford2, Brian D Weitzner2,8, Lance J Stewart2, Adam P Moyer2,9, Maddalena Di Piazza2, Joshua G Whalen2, Per Jr Greisen2,10, David W Christianson1, David Baker11.   

Abstract

Despite recent success in computational design of structured cyclic peptides, de novo design of cyclic peptides that bind to any protein functional site remains difficult. To address this challenge, we develop a computational "anchor extension" methodology for targeting protein interfaces by extending a peptide chain around a non-canonical amino acid residue anchor. To test our approach using a well characterized model system, we design cyclic peptides that inhibit histone deacetylases 2 and 6 (HDAC2 and HDAC6) with enhanced potency compared to the original anchor (IC50 values of 9.1 and 4.4 nM for the best binders compared to 5.4 and 0.6 µM for the anchor, respectively). The HDAC6 inhibitor is among the most potent reported so far. These results highlight the potential for de novo design of high-affinity protein-peptide interfaces, as well as the challenges that remain.

Entities:  

Year:  2021        PMID: 34099674     DOI: 10.1038/s41467-021-23609-8

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  64 in total

1.  Macrocyclic Peptides as Drug Candidates: Recent Progress and Remaining Challenges.

Authors:  Alexander A Vinogradov; Yizhen Yin; Hiroaki Suga
Journal:  J Am Chem Soc       Date:  2019-02-27       Impact factor: 15.419

Review 2.  The Current State of Peptide Drug Discovery: Back to the Future?

Authors:  Antoine Henninot; James C Collins; John M Nuss
Journal:  J Med Chem       Date:  2017-08-11       Impact factor: 7.446

3.  Selective Targeting of Integrin αvβ8 by a Highly Active Cyclic Peptide.

Authors:  Florian Reichart; Oleg V Maltsev; Tobias G Kapp; Andreas F B Räder; Michael Weinmüller; Udaya Kiran Marelli; Johannes Notni; Alexander Wurzer; Roswitha Beck; Hans-Jürgen Wester; Katja Steiger; Salvatore Di Maro; Francesco Saverio Di Leva; Luciana Marinelli; Markus Nieberler; Ute Reuning; Markus Schwaiger; Horst Kessler
Journal:  J Med Chem       Date:  2019-02-06       Impact factor: 7.446

4.  In-solution enrichment identifies peptide inhibitors of protein-protein interactions.

Authors:  Fayçal Touti; Zachary P Gates; Anupam Bandyopadhyay; Guillaume Lautrette; Bradley L Pentelute
Journal:  Nat Chem Biol       Date:  2019-03-18       Impact factor: 15.040

Review 5.  Therapeutic peptides: Historical perspectives, current development trends, and future directions.

Authors:  Jolene L Lau; Michael K Dunn
Journal:  Bioorg Med Chem       Date:  2017-07-01       Impact factor: 3.641

Review 6.  Cyclic peptide therapeutics: past, present and future.

Authors:  Alessandro Zorzi; Kaycie Deyle; Christian Heinis
Journal:  Curr Opin Chem Biol       Date:  2017-02-27       Impact factor: 8.822

Review 7.  Engineered protein scaffolds as leads for synthetic inhibitors of protein-protein interactions.

Authors:  Michael G Wuo; Paramjit S Arora
Journal:  Curr Opin Chem Biol       Date:  2018-05-24       Impact factor: 8.822

8.  Cell-Permeable Bicyclic Peptidyl Inhibitors against NEMO-IκB Kinase Interaction Directly from a Combinatorial Library.

Authors:  Curran A Rhodes; Patrick G Dougherty; Jahan K Cooper; Ziqing Qian; Steffen Lindert; Qi-En Wang; Dehua Pei
Journal:  J Am Chem Soc       Date:  2018-09-11       Impact factor: 15.419

Review 9.  Tumor-targeting peptides from combinatorial libraries.

Authors:  Ruiwu Liu; Xiaocen Li; Wenwu Xiao; Kit S Lam
Journal:  Adv Drug Deliv Rev       Date:  2016-05-19       Impact factor: 15.470

10.  Dual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy.

Authors:  Lai Yue Chan; David J Craik; Norelle L Daly
Journal:  Sci Rep       Date:  2016-10-13       Impact factor: 4.379

View more
  5 in total

1.  Des3PI: a fragment-based approach to design cyclic peptides targeting protein-protein interactions.

Authors:  Maxence Delaunay; Tâp Ha-Duong
Journal:  J Comput Aided Mol Des       Date:  2022-08-06       Impact factor: 4.179

2.  Engineered protein-small molecule conjugates empower selective enzyme inhibition.

Authors:  Andrew K Lewis; Abbigael Harthorn; Sadie M Johnson; Roy R Lobb; Benjamin J Hackel
Journal:  Cell Chem Biol       Date:  2021-08-06       Impact factor: 8.116

3.  Computational Site Saturation Mutagenesis of Canonical and Non-Canonical Amino Acids to Probe Protein-Peptide Interactions.

Authors:  Jeffrey K Holden; Ryan Pavlovicz; Alberto Gobbi; Yifan Song; Christian N Cunningham
Journal:  Front Mol Biosci       Date:  2022-04-14

4.  Accurate de novo design of membrane-traversing macrocycles.

Authors:  Gaurav Bhardwaj; Jacob O'Connor; Stephen Rettie; Yen-Hua Huang; Theresa A Ramelot; Vikram Khipple Mulligan; Gizem Gokce Alpkilic; Jonathan Palmer; Asim K Bera; Matthew J Bick; Maddalena Di Piazza; Xinting Li; Parisa Hosseinzadeh; Timothy W Craven; Roberto Tejero; Anna Lauko; Ryan Choi; Calina Glynn; Linlin Dong; Robert Griffin; Wesley C van Voorhis; Jose Rodriguez; Lance Stewart; Gaetano T Montelione; David Craik; David Baker
Journal:  Cell       Date:  2022-08-29       Impact factor: 66.850

5.  Structure-based prediction of HDAC6 substrates validated by enzymatic assay reveals determinants of promiscuity and detects new potential substrates.

Authors:  Julia K Varga; Kelsey Diffley; Katherine R Welker Leng; Carol A Fierke; Ora Schueler-Furman
Journal:  Sci Rep       Date:  2022-02-02       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.